Cumulus Oncology Overview

Founded in 2017, Cumulus Oncology is Europe's first oncology biotech creation company, specializing in sourcing novel oncology assets from academic institutes, commercial drug discovery groups, and biopharmaceutical companies. The company identifies and develops new oncology treatments targeting unmet medical needs in specific cancer patient populations. Cumulus operates a 'hub and spoke' model, creating high-value spin-out companies and managing them to key value inflection points. The company incorporates artificial intelligence and machine learning platforms into its decision-making process to prioritize targets and assets, focusing on molecularly selected patient sub-groups. Cumulus has successfully raised significant funding rounds, including a £9 million seed financing in January 2024 led by Eos Advisory and the Scottish National Investment Bank. The company has established spin-out companies such as Nodus Oncology, focusing on DNA damage response therapies, and GIO Therapeutics, targeting GPCRs for oncology and inflammation.

Is Cumulus Oncology the right investor for your startup? Browse their investment focus, stage preferences, and geographic scope to see how well they align with your fundraising goals. Your full match score with Cumulus Oncology, along with a list of other relevant VCs, is available on Hopohopo.io.